AML is their lead indication. Until December pancreatic was not really on there radar as a top candidate but the results were apparently very compelling. That is why there is a bunch of talk on it right now. If results continue it will be AML and pancreatic as the top two priorities from my understanding.
Why would they need to scale down the size of management? Their management structure is fairly normal.
News 
Market Data 
Discover 
AI
